IP Library Granted Patent US 11,795,445
Granted Patent B2
US 11,795,445 · App. 17/316,165 · Granted Oct 24, 2023

Engineered phosphopentomutase variant enzymes

Inventors: Scott J. Novick (Palo Alto, CA); Xiang Yi (San Carlos, CA); Nikki Dellas (San Carlos, CA); Oscar Alvizo (Fremont, CA); Jovana Nazor (Milpitas, CA); Da Duan (Foster City, CA); Vesna Mitchell (Santa Clara, CA); Jonathan Vroom (South San Francisco, CA); Santhosh Sivaramakrishnan (Redwood City, CA); Nandhitha Subramanian (Cambridge, GB); Jeffrey C. Moore (Westfield, NJ); Mark Huffman (Rahway, NJ); Agustina Rodriguez-Granillo (Rahway, NJ); Deeptak Verma (Rahway, NJ); Grant S. Murphy (Rahway, NJ); Nicholas Marshall (Rahway, NJ); Jay Russell (Rahway, NJ); Keith A. Canada (Freehold, NJ)
Assignee: Codexis, Inc.
C12N9/90C12N15/52C12N15/74C12N15/815C12Y504/02007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,795,445
App. No.
17/316,165
Filed
May 10, 2021
Granted
Oct 24, 2023
Kind
B2
Art Unit
1652
USPC
435/194
Abstract

The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Claims (12)

1. An engineered polynucleotide sequence encoding an engineered phosphopentomutase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO: 2, wherein the polypeptide sequence of said engineered phosphopentomutase comprises a substitution of D173A and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2.

2. An engineered polynucleotide sequence encoding at least one engineered phosphopentomutase, wherein said polynucleotide sequence comprises at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO: 3, and wherein the engineered polynucleotide sequence of said engineered phosphopentomutase comprises at least one substitution at one or more positions.

3. An engineered polynucleotide sequence encoding at least one engineered phosphopentomutase comprising at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity to SEQ ID NO: 3.

4. The engineered polynucleotide sequence of claim 1 , wherein said engineered polynucleotide sequence is operably linked to a control sequence.

5. The engineered polynucleotide sequence of claim 1 , wherein said engineered polynucleotide sequence is codon optimized.

6. The engineered polynucleotide sequence of claim 1 , wherein said engineered polynucleotide sequence comprises a polynucleotide sequence forth in SEQ ID NO: 3.

7. An expression vector comprising at least one polynucleotide sequence of claim 1 .

8. A host cell comprising at least one expression vector of claim 7 .

9. A host cell comprising at least one engineered polynucleotide sequence of claim 1 .

10. A method of producing an engineered phosphopentomutase in a host cell, comprising culturing a host cell comprising at least one engineered polynucleotide of claim 1 , under suitable conditions, such that at least one engineered phosphopentomutase is produced.

11. The method of claim 10 , further comprising recovering at least one engineered phosphopentomutase from the culture and/or host cell.

12. The method of claim 11 , further comprising the step of purifying said at least one engineered phosphopentomutase.

Assignments (2)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2024
From: NOVICK, SCOTT J.; YI, XIANG; DELLAS, NIKKI; ALVIZO, OSCAR; NAZOR, JOVANA; DUAN, DA; MITCHELL, VESNA; VROOM, JONATHAN; SIVARAMAKRISHNAN, SANTHOSH; SUBRAMANIAN, NANDHITHA; MOORE, JEFFREY C.; HUFFMAN, MARK A.; VERMA, DEEPTAK; MURPHY, GRANT S.; MARSHALL, NICHOLAS M.; RUSSELL, JAY H.; CANADA, KEITH A.; RODRIGUEZ-GRANILLO, AGUSTINA; MERCK SHARP & DOHME; NOVICK, SCOTT J.; YI, XIANG; DELLAS, NIKKI; ALVIZO, OSCAR; NAZOR, JOVANA; DUAN, DA; MITCHELL, VESNA
To: CODEXIS, INC.
Reel/Frame 066529/0216 →